0000000001227971

AUTHOR

F. Ridolfi

showing 2 related works from this author

A simplified clinical risk score predicts the need for early endoscopy in non-variceal upper gastrointestinal bleeding

2014

Abstract Background Pre-endoscopic triage of patients who require an early upper endoscopy can improve management of patients with non-variceal upper gastrointestinal bleeding. Aims To validate a new simplified clinical score (T-score) to assess the need of an early upper endoscopy in non variceal bleeding patients. Secondary outcomes were re-bleeding rate, 30-day bleeding-related mortality. Methods In this prospective, multicentre study patients with bleeding who underwent upper endoscopy were enrolled. The accuracy for high risk endoscopic stigmata of the T-score was compared with that of the Glasgow Blatchford risk score. Results Overall, 602 patients underwent early upper endoscopy, and…

MaleVariceal bleedingClinical scoremedicine.medical_treatmentSeverity of Illness IndexEndoscopy GastrointestinalHEMORRHAGERecurrenceRisk FactorsProspective StudiesAged 80 and overOUTCOMESFramingham Risk Scoremedicine.diagnostic_testIncidenceUpper endoscopyGastroenterologyMiddle AgedTIMESurvival RateItalyFemaleGastrointestinal HemorrhageClinical risk factormedicine.medical_specialtyRisk AssessmentDiagnosis DifferentialClinical score Endoscopy High endoscopic stigmata Upper gastrointestinal bleeding; GLASGOW-BLATCHFORD HEMORRHAGE TIME OUTCOMESmedicineHumansUpper gastrointestinal bleedingAgedHepatologybusiness.industryReproducibility of Resultsnon variceal upper gastrointestinal bleedingEndoscopymedicine.diseaseTriageGLASGOW-BLATCHFORDEndoscopySurgerySettore MED/18 - Chirurgia GeneraleEarly DiagnosisHigh endoscopic stigmataROC CurveTherapeutic endoscopyUpper gastrointestinal bleedingTriagebusinessFollow-Up StudiesDigestive and Liver Disease
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct